Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author José Segarra-Martínez, Anabelca
• dc.contributor.author Sobrevals, Lucianoca
• dc.contributor.author Ivorra Cano, Antoni, 1974-ca
• dc.contributor.author Fillat i Fonts, Cristinaca
• dc.date.accessioned 2016-05-05T13:54:43Z
• dc.date.available 2016-05-05T13:54:43Z
• dc.date.issued 2012ca
• dc.description.abstract Pancreatic Ductal Adenocarcinoma (PDAC) therapies show limited success./nIrreversible electroporation (IRE) is an innovative loco-regional therapy in which highvoltage pulses are applied to induce plasma membrane defects leading to cellular death. In the present study we evaluated the feasibility of IRE against PDAC. IRE/ntreatment exhibited significant antitumor effects and prolonged survival in mice with orthotopic xenografts. Extensive tumor necrosis, reduced tumor cell proliferation and disruption of microvessels were observed at different days post-IRE. Animals had transient increases in transaminases, amylase and lipase enzymes that normalized at/n24h post-IRE. These results suggest that IRE could be an effective treatment for locally advanced pancreatic tumors.en
• dc.description.sponsorship This work was supported by the Spanish/nMinistry of Science and Innovation (MICINN), BIO2008-04692-C03-02/01 and received/npartial support from the Generalitat de Catalunya SGR091527. Anabel José was a/nrecipient of a FPU fellowship from the MICINN. Fillat’s group is also partially funded by/nCIBERER and by IIS10/00014 from Instituto de Salud Carlos III. Ivorra’s research is/ncurrently supported by a Ramón y Cajal fellowship from the Spanish Ministry for/nScience and Innovation and a Marie Curie IRG grant from the European Commission.en
• dc.format.mimetype application/pdfca
• dc.identifier.citation José A, Sobrevals L, Ivorra A, Fillat C. Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models. Cancer Lett. 2012;317(1):16-23. DOI:10.1016/j.canlet.2011.11.004ca
• dc.identifier.doi http://dx.doi.org/10.1016/j.canlet.2011.11.004
• dc.identifier.issn 0304-3835ca
• dc.identifier.uri http://hdl.handle.net/10230/26250
• dc.language.iso engca
• dc.publisher Elsevierca
• dc.relation.ispartof Cancer letters. 2012;317(1):16-23.
• dc.relation.projectID info:eu-repo/grantAgreement/EC/FP7/256376
• dc.relation.projectID info:eu-repo/grantAgreement/ES/3PN/BIO2008-04692-C03-02/01
• dc.rights © Elsevier http://dx.doi.org/10.1016/j.canlet.2011.11.004ca
• dc.rights.accessRights info:eu-repo/semantics/openAccessca
• dc.subject.keyword Pancreatic ductal adenocarcinomaen
• dc.subject.keyword Irreversible electroporationen
• dc.subject.keyword Orthotopic pancreatic cancer xenograftsen
• dc.subject.keyword Bioluminescent imagingen
• dc.title Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse modelsca
• dc.type info:eu-repo/semantics/articleca
• dc.type.version info:eu-repo/semantics/acceptedVersionca